Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

Bullboard Posts
Comment by Surathanion Jun 12, 2020 10:31am
81 Views
Post# 31143055

RE:RE:Closed under the 200MA today, next stop 0.03 and R/S

RE:RE:Closed under the 200MA today, next stop 0.03 and R/SEddie might very well be a basher but he is not far off as I have been here for approx 7 years and trip has never and I mean never come through on anything.  He is an incompetant CEO.

Billing issues: took over a year to resolve and then they walked away from all the money that was owed them, over 1.5 million if memory serves me correct.

Projected increase in sales: never materialized and over the last few years has actually been decreasing!

Trip hint that we would have $30 mil in revenues: Lie and never materialized.

Oncore deal: zero from that so far.  Except for the one news release, do we ever hear of anything else from Oncore.....nope.  We are certainly not seeing any revenues are we?

Launch of telehealth: except for one single fluffy news release on the fact they got some queries on thier website......what are the stats now? How much has resulted in revenue/orders?  I bet you pennies considering the last quarterly numbers. Wht do we never hear on "hit" stats...maybe because they only get a few a month?

And Eddie mentioned consolidation.....100% correct, See 20 June 2019 news release on stockhouse. Trip can call for a consolidation of shares anytime he wants and I predict early 2021.

Here is what is going to happen.  ongoing PP and major dilution will close. then Trip will announce another major PP and dilution late in the year or early 2021 followed by an immeddiate consolidation of shares in 2021.

Unless they can actually get some revenues from the COVID-19 testing and ramp up their sales of their own products, we will continue to bounce between $0.03 and $0.15 with luck maybe the odd spike to $0.20.

Surathani




Bullboard Posts